Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.

• Nakamura, Yoichi

• Soda, Hiroshi

• Oka, Mikio

• Kinoshita, Akitoshi

• Fukuda, Minoru

• Fukuda, Masaaki

• Takatani, Hiroshi

• Nagashima, Seiji

• Soejima, Yoshifumi

• Kasai, Takashi

• Nakatomi, Katsumi

• Masuda, Noriyuki

• Tsukamoto, Kazuhiro

• Kohno, Shigeru

Abstract

Irinotecan-containing regimens are known to be active and tolerable in patients with non-small cell lung cancer (NSCLC). A randomized phase II trial was conducted to evaluate the efficacy of irinotecan plus paclitaxel or gemcitabine for previously untreated stage IIIB or stage IV NSCLC.

Journal of Thoracic Oncology, 6(1), pp.121-127; 2011

Journal

• Journal of Thoracic Oncology : official publication of the International Association for the Study of Lung Cancer

  Journal of Thoracic Oncology : official publication of the International Association for the Study of Lung Cancer 6 (1), 121-127, 2011-01

  Lippincott Williams & Wilkins Ltd.

Keywords

• Gemcitabine
• Irinotecan
• NSCLC
• Paclitaxel
• UGT1A1*27
• UGT1A1*6

Details

• CRID: 1050005822274748544
• NII Article ID: 120006984817
• ISSN: 15561380
• HANDLE: 10069/27360
• Web Site: https://nagasaki-u.repo.nii.ac.jp/records/14758
• Text Lang: en
• Article Type: journal article
• Data Source:
  • IRDB
  • CiNii Articles